Cargando…

Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities

This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, siz...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghaferi, Mohsen, Amari, Samar, Vivek Mohrir, Bhalchandra, Raza, Aun, Ebrahimi Shahmabadi, Hasan, Alavi, Seyed Ebrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151690/
https://www.ncbi.nlm.nih.gov/pubmed/32168743
http://dx.doi.org/10.3390/ph13030044
_version_ 1783521307902607360
author Ghaferi, Mohsen
Amari, Samar
Vivek Mohrir, Bhalchandra
Raza, Aun
Ebrahimi Shahmabadi, Hasan
Alavi, Seyed Ebrahim
author_facet Ghaferi, Mohsen
Amari, Samar
Vivek Mohrir, Bhalchandra
Raza, Aun
Ebrahimi Shahmabadi, Hasan
Alavi, Seyed Ebrahim
author_sort Ghaferi, Mohsen
collection PubMed
description This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats.
format Online
Article
Text
id pubmed-7151690
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71516902020-04-20 Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities Ghaferi, Mohsen Amari, Samar Vivek Mohrir, Bhalchandra Raza, Aun Ebrahimi Shahmabadi, Hasan Alavi, Seyed Ebrahim Pharmaceuticals (Basel) Article This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats. MDPI 2020-03-11 /pmc/articles/PMC7151690/ /pubmed/32168743 http://dx.doi.org/10.3390/ph13030044 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ghaferi, Mohsen
Amari, Samar
Vivek Mohrir, Bhalchandra
Raza, Aun
Ebrahimi Shahmabadi, Hasan
Alavi, Seyed Ebrahim
Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
title Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
title_full Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
title_fullStr Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
title_full_unstemmed Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
title_short Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
title_sort preparation, characterization, and evaluation of cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved in vitro and in vivo anticancer activities
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151690/
https://www.ncbi.nlm.nih.gov/pubmed/32168743
http://dx.doi.org/10.3390/ph13030044
work_keys_str_mv AT ghaferimohsen preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities
AT amarisamar preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities
AT vivekmohrirbhalchandra preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities
AT razaaun preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities
AT ebrahimishahmabadihasan preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities
AT alaviseyedebrahim preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities